10 stories mentioning HKG:2607Updated 3d ago
Every FINWIRES story that references HKG:2607, newest first.
Shanghai Pharmaceuticals (SHA:601607, HKG:2607) will pay out a cash dividend of 0.10 yuan per share for the first half to holders of its Shanghai-listed A shares, according to a Friday bourse filing in Shanghai.The dividend will be distributed on Sept. 18 to shareholders on record as of Sept. 17.The pharmaceutical company's Hong Kong shares slipped 1% during the morning trade, while its Shanghai shares fell marginally.
Shanghai Pharmaceuticals (SHA:601607, HKG:2607) subsidiary Changzhou Pharmaceutical Factory received drug registration certificates from China's National Medical Products Administration for its ruxolitinib phosphate tablets, according to a Tuesday disclosure to the Shanghai bourse.The drug is indicated for myelofibrosis, a form of blood cancer, and graft-versus-host disease in patients aged 12 years and older with inadequate response to glucocorticoids or other systemic therapies, the filing said.The drug company's shares rose nearly 2% in Hong Kong during the midday break on Tuesday.
Shanghai Pharmaceuticals (SHA:601607, HKG:2607) reported 3.5 billion yuan in profit attributable to equity holders for the first half, compared with 4.46 billion yuan a year ago, a Thursday bourse filing showed.EPS moved to 0.95 yuan from 1.20 yuan year over year.For the six months ended June 30, operating revenue was 147.5 billion yuan, versus 141.6 billion yuan previously, the pharmaceutical company said.The company proposed an interim dividend of 1 yuan per 10 shares for the period.
Shanghai Pharmaceuticals (SHA:601607, HKG:2607) proposed that its unit, Shanghai Pharmaceutical Holding, dispose of its 51% holdings in subsidiary, Shanghai Shangyao Xinte Dong'an Pharmacy, through public listing, according to a Tuesday disclosure on the Shanghai bourse.The proposed minimum listing price is 178.5 million yuan.Shangyao Xinte sells pharmaceuticals and operates Class III medical devices.After the completion of the transaction, the pharmaceutical company will no longer include Shangyao Xinte in its consolidated financial statements.
Shanghai Pharmaceuticals' (SHA:601607, HKG:2607) unit, Shanghai Shangyao Xinyi Pharmaceutical Factory, received a drug registration certificate from China's National Medical Products Administration for omeprazole and sodium bicarbonate dry suspension (I), according to a Shanghai bourse filing on Tuesday.The drug is used for the treatment of active duodenal ulcers and gastroesophageal reflux disease.The pharmaceutical company invested 5.9 million yuan into the research and development of the drug.The company's Hong Kong shares slipped 1% during the morning trade.
Shanghai Pharmaceuticals (SHA:601607, HKG:2607) decided to terminate the clinical trial and development of salvianolic acid A for injection, according to a Shanghai bourse filing on Saturday.The Chinese pharmaceutical company's Hong Kong shares rose 2% during Monday's afternoon trade.The drug was intended for the treatment of angina pectoris associated with coronary heart disease.The company said the decision was made to optimize the allocation of funds on projects with "greater strategic advantages".
Shanghai Pharmaceuticals (SHA:601607, HKG:2607) received clinical trial approval from China's National Medical Products Administration for its Qingrun Yangmu traditional Chinese drug, according to a Tuesday filing with the Shanghai bourse.Qingrun Yangmu, developed by subsidiary Shanghai Pharmaceuticals Group Institute of Traditional Chinese Medicine, is indicated for dry eye.
Shanghai Pharmaceuticals (SHA:601607, HKG:2607) subsidiary Shanghai Pharmaceutical Holdings will sell a 41% stake in subsidiary Shanghai Pharmaceutical Yiyao Pharmaceutical (Shanghai) for 329.8 million yuan via a public listing, according to a Saturday filing with the Shanghai bourse.Following the transaction, Shanghai Pharma Holdings' ownership in the unit will drop from 51% to 10% and Shanghai Pharmaceutical Holdings will no longer be part of its financial statements.
Shanghai Pharmaceuticals (SHA:601607, HKG:2607) received a drug registration certificate from China's National Medical Products Administration for the manufacturing of Roxadustat capsules, according to a Shanghai bourse filing on Saturday.The pharmaceutical company's Hong Kong shares rose 1% during Monday's afternoon trade.The drug is used for the treatment of anemia caused by chronic kidney disease.
Shanghai Pharmaceuticals (SHA:601607, HKG:2607) recorded a 6.4% rise in attributable profit in the first quarter of 2026 to 1.42 billion yuan from 1.33 billion yuan a year prior, according to a Wednesday Hong Kong bourse filing.The pharma company's earnings per share rose to 0.3823 yuan from 0.3595 yuan in the corresponding period of the previous fiscal year.Revenue jumped 6.4% to 75.3 billion yuan from 70.8 billion yuan in the year-ago period.
